参考文献/References:
[1]Denton CP,Khanna D.Systemic sclerosis[J].Lancet,2017,390(10103):1685-1699. [2]Yang D,Han Z,Oppenheim JJ.Alarmins and immunity.Immunol[J].Immunological Reviews,2017,280(1):41-56. [3]Máca J,Peteja M.Alarmins and surgical injury[J].Rozhl Chir,2017,96(3):105-113. [4]Hayashi T,Momota M,Kuroda E,et al.DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination[J].Front Immunol,2018(9):2619. [5]Man SM,Karki R,Kanneganti TD.Molecular mechanisms and functions of pyroptosis,inflammatory caspases and inflammasomes in infectious diseases[J].Immunological Reviews,2017,277(1):61-75. [6]Patel S.Danger-Associated Molecular Patterns (DAMPs): the Derivatives and Triggers of Inflammation[J].Curr Allergy Asthma Rep,2018,18(11):63. [7]魏佳鑫,张莹,马晓媛,等.警报素高迁移率族蛋白B1在脓毒症中的作用[J].中华危重病急救医学,2016,28(8):761-764. [8]Colavita L,Ciprandi G,Salpietro A,et al.HMGB1: A pleiotropic activity[J].Pediatr Allergy Immunol,2020,31(Suppl 26):63-65. [9]Zhu Z,Hu X.HMGB1 induced endothelial permeability promotes myocardial fibrosis in diabetic cardiomyopathy[J].International Journal Of Cardiology,2017(227):875. [10]Yoshizaki A,Komura K,Iwata Y,et al.Clinical Significance of Serum HMGB-1 and sRAGE Levels in Systemic Sclerosis:Association with Disease Severity[J].Journal of Clinical Immunology,2009(29):180-189. [11]Maugeri N,Capobianco A,Rovere-Querini P,et al.Platelet microparticles sustain autophagy-associated activation of neutrophils in systemic sclerosis[J].Science Translational Medicine,2018(10):eaao3089. [12]Sorensen OE,Borregaard N.Neutrophil extracellular traps-The dark side of neutrophils[J].Journal Of Clinical Investigation,2016(126):1612-1620. [13]Maugeri N,Rovere-Querini P,Baldini M,et al.Oxidative Stress Elicits Platelet/Leukocyte Inflammatory Interactions via HMGB1:A Candidate for Microvessel Injury in Sytemic Sclerosis[J].Antioxidants&Redox Signaling,2014(20):1060-1074. [14]Cayrol C,Girard JP.Interleukin-33(IL-33): A nuclear cytokine from the IL-1 family[J].Immunol Rev,2018,281(1):154-168. [15]Yanaba K,Yoshizaki A,Asano Y,et al.Serum IL-33 levels are raised in patients with systemic sclerosis:Association with extent of skin sclerosis and severity of pulmonary fibrosis[J].Clinical Rheumatology,2011,30(6):825-830. [16]Luzina IG,Pickering EM,Kopach P,et al.Full-Length IL-33 Promotes Inflammation but not Th2 Response In Vivo in an ST2-Independent Fashion[J].Journal Of Immunology,2012,189(1):403-410. [17]Terras S,Opitz E,Moritz RKC,etal.Increased serum IL-33 levels may indicate vascular involvement in systemic sclerosis[J].Annals of the Rheumatic Diseases,2013,72(1):144-145. [18]Anders HJ.Of Inflammasomes and Alarmins: IL-1β and IL-1α in Kidney Disease[J].J Am Soc Nephrol,2016,27(9):2564-2575. [19]Huang XL,Wu GC,Wang YJ,et al.Association of interleukin-1 family cytokines single nucleotide polymorphisms with susceptibility to systemic sclerosis:An independent case-control study and a meta-analysis[J].Immunologic Research,2016,64(6):1041-1052. [20]Su H,Rei N,Zhang L,et al.Meta-analyses of IL1A polymorphisms and the risk of several autoimmune diseases published in databases[J].PLoS One,2018,13(6):e0198693. [21]Aden N,Nuttall A,Shiwen X,et al.Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis[J].J Invest Dermatol,2010,130(9):2191-2200. [22]Zhao L,Lu W.Defensins in innate immunity[J].Curr Opin Hematol,2014,21(1):37-42. [23]Kuzumi A,Yoshizaki A,Fukasawa T,et al.Serum levels of human β-defensin 2:Possible association with fibrosis and vasculopathy in patients with systemic sclerosis[J].J Eur Acad Dermatol Venereol,2019,33(7):e272-e274. [24]Yoshizaki A.Pathogenic roles of B lymphocytes in systemic sclerosis[J].Immunology Letters,2018(195):76-82. [25]Sakamoto N,Ishimatsu Y,Kakugawa T,et al.Elevated plasma α-defensins in patients with acute exacerbation of fibrotic interstitial pneumonia[J].Respir Med,2015,109(2):265-271. [26]Kim HJ,Cho DH,Lee KJ,et al.LL-37 suppresses sodium nitroprusside-induced apoptosis of systemic sclerosis dermal fibroblasts[J].Exp Dermatol,2011,20(10):843-845. [27]Takahashi T,Asano Y,Nakamura K,et al.A potential contribution of antimicrobial peptide LL-37 to tissue fibrosis and vasculopathy in systemic sclerosis[J].Br J Dermatol,2016,175(6):1195-1203. [28]Ogawa F,Shimizu K,Hara T,et al.Serum levels of heat shock protein 70, a biomarker of cellular stress,are elevated in patients with systemic sclerosis:Association with fibrosis and vascular damage[J].Clin Exp Rheumatol,2008(26):659-662. [29]Ogawa F,Shimizu K,Hara T,et al.Autoantibody against one of the antioxidant repair enzymes,methionine sulfoxide reductase A,in systemic sclerosis: Association with pulmonary fibrosis and vascular damage[J].Arch Dermatol Res,2010(302):27-35. [30]Misunová M,Svitálková T,Plestilová L,et al.Molecular markers of systemic autoimmune disorders:The expression of MHC-located HSP70 genes is significantly associated with autoimmunity development[J].Clin Exp Rheumatol,2017(35):33-42. [31]Giusti L，Sernissi F，Donadio E.Salivary psoriasin (S100A7) correlates with diffusion capacity of carbon monoxide in a large cohort of systemic sclerosis patients[J].J Transl Med,2016(14):262. [32]Nikitorowicz-Buniak J,Shiwen X,Denton CP,etal.Abnormally Differentiating Keratinocytes in the Epidermis of Systemic Sclerosis Patients Show Enhanced Secretion of CCN2 and S100A9[J].J Investig Dermatol,2014(134):2693-2702.
相似文献/References:
[1]孙 杰,李 洋.系统性硬化症纤维化治疗新靶点研究[J].医学信息,2018,31(09):56.[doi:10.3969/j.issn.1006-1959.2018.09.018]
SUN Jie,LI Yang.A New Target for the Treatment of Systemic Sclerosis with Fibrosis[J].Medical Information,2018,31(04):56.[doi:10.3969/j.issn.1006-1959.2018.09.018]
[2]程丽丽,黄传兵,汤忠富,等.从肺论治系统性硬化症合并间质性肺病的经验举隅[J].医学信息,2022,35(10):155.[doi:10.3969/j.issn.1006-1959.2022.10.039]
[3]王海燕,唐小葵.系统性硬化症相关间质性肺病的治疗[J].医学信息,2018,31(19):60.[doi:10.3969/j.issn.1006-1959.2018.19.020]
WANG Hai-yan,TANG Xiao-kui.Treatment of Systemic Sclerosis-related Interstitial Lung Disease[J].Medical Information,2018,31(04):60.[doi:10.3969/j.issn.1006-1959.2018.19.020]
[4]陈 英,周淑红,王 妍,等.硬皮病相关间质性肺病与特发性肺纤维化的临床比较[J].医学信息,2023,36(10):53.[doi:10.3969/j.issn.1006-1959.2023.10.013]
CHEN Ying,ZHOU Shu-hong,WANG Yan,et al.Clinical Comparison Between Scleroderma Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis[J].Medical Information,2023,36(04):53.[doi:10.3969/j.issn.1006-1959.2023.10.013]